IONS
IONIS PHARMACEUTICALS INCPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Jun 25 to Jul 7 ▼ 4 days of insider sells: $12.9M by 9 insiders, avg $81.03
- Jul 30 to Jul 31 ▲ 2 days of insider buys: $1.1M by 1 insider, avg $52.94
- Sep 4 ▼ Ionis Pharmaceuticals announced that its partner Novartis reported t…
- Sep 4 ▲ Ionis Pharmaceuticals announced FDA approval of ZANVASTRO (zilganers…
- Sep 23 ▲ Ionis and partner Roche reported positive prespecified interim resul…
- Oct 16 ▼ 2 insiders sell $61.4K at $43.54
- Oct 21 ▲ Ionis Pharmaceuticals' partner GSK announced FDA approval of HIBSAGO…
- Oct 22 ▲ BMO Capital upgrades
- Oct 23 ▲ Ionis partner Roche announced positive Phase 3 IMAgINATION data for…
- Oct 26 FDA decision: PDUFA: IONS, bepirovirsen in chronic hepatitis B (CHB), 20…
- Nov 9 ▼ Total revenue, DAWNZERA guidance, operating loss and cash guidance w…
- Nov 10 ▲ 1 insider buy $148.2K at $29.64
Signal stack
Where each data set points today.
- InsidersBEARISH
1 insider bought $1.2M at an average $48.28. 10 insiders sold $12.9M. Price is 40% below their cost.
- InstitutionsMIXED
Q3 2026: 44 added (1 new), 39 trimmed or exited.
- AnalystsBULLISH
27 of 32 rate it Buy or better. Every target is above the price.
- Short sellersSTEADY
Short interest +2.5% to 21.17M shares. 8.4 days to cover, ≈12.7% of shares.
- TrendDOWNTREND
33% below its 50-day average. New closing low $27.31 on Nov 12.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| STATE STREET CORP | ADD | $255.0M |
| MORGAN STANLEY | DOUBLED | $140.4M |
| WESTFIELD CAPITAL MANAGEMENT CO LP | DOUBLED | $107.2M |
| Qube Research & Technologies Ltd | DOUBLED | $89.1M |
| UBS Group AG | DOUBLED | $67.3M |
| AMERICAN CENTURY COMPANIES INC | TRIM | $51.7M |
| Squarepoint Ops LLC | DOUBLED | $50.2M |
| JPMORGAN CHASE & CO | TRIM | $45.2M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
32 analystsPrice is below the lowest target. Median implies +141%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 10, 2026 | Goldman Sachs MAINTAIN | Neutral |
| Nov 10, 2026 | Morgan Stanley MAINTAIN | Overweight |
| Nov 10, 2026 | TD Cowen MAINTAIN | Buy |
| Nov 10, 2026 | Oppenheimer MAINTAIN | Outperform |
| Nov 10, 2026 | RBC Capital MAINTAIN | Outperform |
| Nov 10, 2026 | Wells Fargo MAINTAIN | Overweight |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Hayden Michael R Director Nov 10, 2026 | BUY | $148.2K |
Swayze Eric EVP Research Oct 16, 2026 | SELL | $2.3K |
Devers Shannon L. EVP, Chief Human Resources Ofc Oct 16, 2026 | SELL | $59.1K |
Swayze Eric EVP Research Oct 15, 2026 | EXERCISE | 125 sh |
Devers Shannon L. EVP, Chief Human Resources Ofc Oct 15, 2026 | EXERCISE | 2,820 sh |
O'NEIL PATRICK R. EVP CLO & General Counsel Aug 31, 2026 | OTHER | $3.2K |
Birchler Brian EVP, Corp and Development Ops Aug 31, 2026 | OTHER | $3.0K |
Monia Brett P Chief Executive Officer Aug 31, 2026 | OTHER | $5.0K |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Washington
Short side
FINRA· Oct 30, 2026SecBot reports
26 filings · 7 bullish · 3 bearish · 3 mixed · 13 neutral- BEARISH 8-KNov 9, 2026
Total revenue, DAWNZERA guidance, operating loss and cash guidance were reaffirmed.
The TRYNGOLZA launch miss is the key negative surprise, cutting the flagship product's 2026 outlook in half. Monitor Q4 2026 TRYNGOLZA sales and any further guidance changes; the DAWNZERA and…
- MIXED INST-CLUSTEROct 27, 2026
In Q2 2026, 45 institutional buyers accumulated $162.9M in IONS while 32 sellers reduced holdings…
The cluster shows a clear divergence: active asset managers and quant funds are accumulating, while several large quant funds (Millennium, D.E. Shaw) are trimming. The insider buying adds…
- BULLISH 8-KOct 23, 2026
Ionis partner Roche announced positive Phase 3 IMAgINATION data for sefaxersen in IgA nephropathy…
The strong proteinuria reduction and clean safety profile position sefaxersen as a potential best-in-class IgAN therapy. Watch for regulatory submission timing and the week 105 eGFR data, which will…
- BULLISH 8-KOct 21, 2026
Ionis Pharmaceuticals' partner GSK announced FDA approval of HIBSAGO (bepirovirsen) for chronic…
Monitor GSK's commercial launch execution and initial prescription data for HIBSAGO, as well as upcoming regulatory decisions in ex-US geographies which could trigger milestone payments to Ionis.
All IONS filing & press-release reports (26)
- 8-K reportNov 9, 2026
- INST-CLUSTER reportOct 27, 2026
- 8-K reportOct 23, 2026
- 8-K reportOct 21, 2026
- INST-CLUSTER reportOct 21, 2026
- 8-K reportSep 23, 2026
- 8-K reportSep 4, 2026
- 8-K reportSep 4, 2026
- INSIDER-BUY reportJul 31, 2026
- 8-K reportJul 29, 2026
- 8-K reportJul 9, 2026
- CLUSTER reportJul 9, 2026
- CLUSTER reportJul 9, 2026
- 8-K reportJul 9, 2026
- CLUSTER reportJun 30, 2026
- CLUSTER reportJun 30, 2026
- CLUSTER reportJun 26, 2026
- 8-K reportJun 24, 2026
- CLUSTER reportJun 16, 2026
- 8-K reportJun 12, 2026
- 8-K reportJun 8, 2026
- 8-K reportMay 28, 2026
- CLUSTER reportApr 28, 2026
- 8-K reportApr 21, 2026
- CLUSTER reportApr 16, 2026
- 8-K reportFeb 25, 2026